EDGE
Get a demo
Log In

Psychedelic Medicine

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Overview

The psychedelic renaissance: Moving beyond stigma toward a breakthrough mental health treatment

Psychedelics (also called hallucinogens) are powerful mind-altering substances that can temporarily induce hallucinations by affecting serotonin receptors in the brain that are responsible for controlling the senses. Popular psychedelics include lysergic acid diethylamide (LSD/acid), psilocybin (magic mushrooms), and ketamine.

Psychedelics have been used in religious settings for thousands of years; however, social stigma in the 1960s developed due to widespread recreational use by “hippies” and youth involved in counter-cultural and anti-war movements in the US and beyond. These substances were finally made illegal in the US in 1970. Fifty years later, psychedelics are re-entering the mainstream as a potential breakthrough for various hard-to-treat mental health conditions, including depression and post-traumatic stress disorders (PTSD). 

A May 2019 approval by the US Food and Drug Administration (FDA) of a ketamine-derivative substance (in therapeutic settings) has raised the possibilities of more widespread commercialisation of psychedelics. Since then, the nascent industry—still mostly in the research stage—has garnered significant investor interest, some of whom are anticipating a cannabis-like boom.

What's driving this industry?

Industry Updates

View all updatesicon
Market Sizing

The US addressable market for FDA-approved depression and PTSD therapies is estimated to be USD 71.6 billion - 143.2 billion

Conservative case

USD 0.0 Bn

Base case

USD 0.0 Bn

Expansion case

USD 0.0 Bn

View details

Market Mapping


Research and development dominates the industry’s competitive landscape

A majority of the businesses in the psychedelic industry focus on research and development (R&D), studying the benefits of psychedelic substances and conducting preclinical and clinical research. Other segments—such as cultivation, clinics, and delivery platforms—have started to evolve only recently, driven by the advancements in R&D and positive developments in the regulatory landscape. So in addition to R&D focused leaders Compass Pathways and MindMed, the industry is now seeing growth in vertically integrated psychedelic players such as Field Trip, Numinus, New Wave, and others listed in the table below.

Incumbents
Growth
Early
Seed
Pre-Seed

The Disruptors


Funding History

Competitive Analysis


Filter by a segment or companies of your choice
expand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

Incumbents


Industry yet to attract interest from big pharma

The psychedelic industry has not yet attracted major interest from conventional pharmaceutical companies. This reluctance could be due to psychedelic therapies’ tendency to require a single round of treatment as well as financial, legal, and reputational risks. Partnerships and acquisitions are highly likely in the near future, however, as psychedelic companies progress toward latter stages of drug development.

In House Development
M&A
Partnership
Investment
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Notable Investors


?
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.